Mucosis receives finan­cial sup­port from the dutch gov­ern­ment for its FluGEM pro­gram

Dutch vac­cine devel­op­ment com­pa­ny Mucosis B.V. announced today that it has received an inno­va­tion cred­it line of approx­i­mate­ly € 3 mil­lion from Agentschap NL, an agency of the Dutch Ministry of Economic Affairs. Mucosis will use this loan towards the clin­i­cal devel­op­ment of its lead prod­uct FluGEM™, an influen­za vac­cine that can be admin­is­tered by a sim­ple spray in the nose. The loan will be redeemed only if the FluGEM™ clin­i­cal devel­op­ment pro­gram is con­clud­ed suc­cess­ful­ly.

“We are real­ly pleased with the government’s finan­cial sup­port. This non-dilu­tive fund­ing under­lines the progress we have made so far and, even more impor­tant­ly, strength­ens our finan­cial capa­bil­i­ties going for­ward. It will enable us to gen­er­ate proof of effi­ca­cy with FluGEM™ in man” said Govert Schouten, CEO of Mucosis.

Mucosis devel­ops nov­el vac­cines on the basis of its unique Mimopath™ tech­nol­o­gy. This inven­tion is key to the growth strat­e­gy for the com­ing years.

Leave a Reply

Your email address will not be published. Required fields are marked *